General Anesthesia

3
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Fresenius Kabi
DIPRIVANApproved
propofol
Fresenius Kabi
General Anesthetic [EPC]injection1989
U
PROPOFOLApproved
propofol
Unknown Company
General Anesthetic [EPC]injection2025

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
1
1
PropofolPhase 31 trial
Active Trials
NCT01856998Completed71
Ambu
AmbuDenmark - Ballerup
1 program
tracheal intubationN/A1 trial
Active Trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fresenius KabiPropofol
Ambutracheal intubation

Clinical Trials (2)

Total enrollment: 71 patients across 2 trials

Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery

Start: May 201371 patients
Phase 3Completed
NCT02002364Ambutracheal intubation

Comparison of a Single Use (Ambu aScope) and a Reusable Flexible Optical Scope for Intubation Through a Supraglottic Airway Device (Aura-i)

Start: Nov 2013
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space